Its main use is in colon cancer, particularly in combination with other chemotherapy agents. This includes the regimen FOLFIRI which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.

Irinotecan is marketed by Pfizer as Camptosar. It is also known as CPT-11.

Side effects

Irinotecan is associated with severe diarrhea, sometimes leading to hospitalization for dehydration. This side effect is managed with the aggressive use of antidiarrheals such as loperamide or Lomotil with the first loose bowel movement.

Read more at Wikipedia.org

• [List your site here Free!]


	Camptosar label should include genotype data, FDA panel says.(Clinical Rounds) : An article from: Family Practice News $5.95	Aceon, invader UGT1A1 molecular assay.(New & Approved) : An article from: Family Practice News $5.95


Camptosar (irinotecan injection, Pharmacia) A first-line chemotherapeutic agent for patients with metastatic colorectal cancer, in combination with 5-fluorouracil/leucovorin ... From OB/GYN News, 6/15/00 by Elizabeth Mechcatie

Genzyme Launches Colorectal Cancer Test to Determine Appropriate Camptosar® Dosage Preferred Partnership With Third Wave Advances Personalized Medicine CAMBRIDGE, Mass., Dec. 6 /PRNewswire-FirstCall/ -- Genzyme Corporation today ... From PR Newswire, 12/6/05

Serious overdoses with Camptosar Does this vial of the new anticancer agent Camptosar Injection (irinotecan HCI injection) contain 20 mg or 100 mg? If you said 20 mg, then you were as ... From Nursing, 1/1/97 by Cohen, Michael R

Breasts: an owner's manual - mind body - Cover Story They nurse our children and cradle lovers; they peek out of V-neck tops or hide demurely behind high-collared blouses, From puberty to postmenopause, ... From Essence, 10/1/02

Colon and rectal cancer drug - Food and Drug Administration approves Camptosar, or irinotecan - Brief Article A new drug to treat advanced colon and rectal cancer was approved by FDA just four days after an agency advisory committee recommended the approval. Camptosar ... From FDA Consumer, 9/1/96

FDA approves Avastin In February, the US Food and Drug Administration (FDA) approved Avastin (bevacizumab) for the treatment of advanced colorectal cancer. Avastin is an ... From Townsend Letter for Doctors and Patients, 5/1/04 by Ralph Moss, W.

New protease inhibitor atazanavir approved - Reyataz™ - Reyataz On June 20 the FDA approved the new once-a-day protease inhibitor atazanavir (brand name Reyataz), manufactured by Bristol-Myers Squibb. Atazanavir has little effect on the blood lipids cholesterol From AIDS Treatment News, 6/27/03

Pierre Fabre Licenses Pharmagenesis Anti-Cancer Herbal Drug Pharmagenesis, Inc., a research and development company based in Palo Alto developing anti-cancer therapies, has signed an agreement with Pierre Fabre ... From Worldwide Biotech, 5/1/03

Home

Contact

Resources

Exchange Links

ebay